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Abstract: Pathophysiology advances in the treatment of pulmonary hypertension
The pulmonary hypertension (PH) is the disease with still not clear pathophysiology. The possibilities 
of current pharmacological treatment of this disorder are unfortunately relatively small, thus the 
advances in searching of new agents effective in this disease are in progress. The article briefly 
discusses the present PH classification, its basic etiopathogenesis description and the current 
and potential possibilities of the pharmacological intervention.
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INTRODUCTION. BASIC DEFINITION 
AND CLASSIFICATION OF PULMONARY HYPERTENSION
Pulmonary hypertension (PH) is a haemodynamic and pathophysiological con-
dition occuring in multiple clinical conditions. According to latest ESC/ERS 
(European Society of Cardiology and European Respiratory Society) guidelines 
form 2009, it is regarded to be an increase in mean pulmonary arterial pres-
sure (mPAP) ≥  25 mm Hg at rest, demonstrated during right heart catheterisa-
tion. Normal mPAP at rest is about 14  ±  3 mm Hg, with upper limit of about 
20 mm Hg, thus value of 25 mm Hg has been chosen as a significant marker 
of PH (the significance of mPAP between 21–24 is unclear and requeires further 
evaluation in epidemiological studies) [1].
Previously PH was mostly described as either a systolic pulmonary artery 
pressure (PAP) of ≥  35 mm Hg or alternatively as a mean pulmonary artery 
pressure (mPAP) ≥  25 mm Hg at rest or  ≥  30 mm Hg with exertion in the pres-
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ence of normal or reduced cardiac output [2–4]. However, the PH definition 
based on the exercise PAP assessement is not supported at the present, be-
cause of the findings showing that healthy individuals can achieve even higher 
values. Thus, the only accepted PH definition is this one due to the resting PAP 
estimation [1].
Pulmonary hypertension was first described in 1865 by the German physi-
can Klob, who reported in his autopsy of a patient who died at age 59 present-
ing progressive ankle oedemas, dyspnoea and cyanosis, findings of narrowing 
of the finer branches of the pulmonary artery with arteriosclerosis. The similar 
clinical course in 24 years old patient reported Romberg in 1891, who also 
observed massive right ventricular hypertrophy. The next, recurrent cases of 
these kind of abnormalities resulted in “Ayerza’s disease” defining in 1913 by 
argentinean physician Arrillaga, who honoured in this way his Professor name, 
also working on this research area [5].
For many years, the explanation of pulmonary hypertension remains mys-
terious and this clinical entity was regarded to be a result of unknown ei-
ther primary or secondary factors. In 1957, PH was divided into 5 classes, 
according to the predominance cause and histopathological features: chronic 
bronchitis and emphysema, left to right shunt, primary pulmonary hyperten-
sion, primary pulmonary arteriosclerosis and pulmonary embolismus [5]. The 
progress in PH understanding that had been made over the years resulted in 
renewed division. The current PH classifications take various aspects of this 
disease into account. There is a pathophysiological PH division into three main 
classess: pre-capillary, post-capillary and mixed ones, based both on anatomi-
cal features and haemodynamic findings of the major parameters: mPAP, PWP 
(pulmonary wedge pressure) and CO (cardiac output). The pre-capillary PH is 
characterized by resting mPAP  ≥  25 mm Hg (in accordance with general defini-
tion) and PWP  ≤  15 mm Hg with normal or reduced CO. Contrary to the above, 
post-capillary PH is diagnosed on the basis of PWP  >  15 mm Hg and the same 
other abnormalities (resting mPAP  ≥  25 mm Hg, CO normal or reduced) [1]. 
The most used PH classification, however, is the clinical one. The actual ver-
sion, established at Dana Point meeting, is a slightly modificated Evian-Venice 
classification proposed in 1998 and 2003. The conditions proceeding with PH 
are divided into five groups, according to the clinical and therapeutical options 
(Table 1). The comparison of the both pathophysiological and clinical PH divi-
sion indicates, that PH patients classified according to clinical description to 
group 1, 3, 4 and 5, are mostly suspected to develop pre-capillary mechanisms 
of PH, while those ones suffering from PH due to left heart disease — group 2, 
are meeting the criteria of post-capillary PH [1].
109
T a b l e  1  —  T a b e l a  1
Clinical classification of pulmonary hypertension (Dana Point, 2009) [1]
Kliniczna klasyfikacja nadciśnienia płucnego według ustaleń  
IV Światowego Sympozjum Nadciśnienia Płucnego (Dana Point, 2009) [1]
1. Pulmonary arterial hypertension (PAH) 1.1. Idiopathic
1.2. Heritable
1.3. Drugs and toxins
1.4. Associated with (APAH)
— connective tissue diseases
— HIV infection
— portal hypertension
— congenital heart disease
— schistosomiasis
— chronic haemolytic anaemia
1.5.  Persistent pulmonary hypertension of the 
newborn
1’ Pulmonary veno-occlusive disease and/or 
pulmonary capillary haemangiomatosis
2.  Pulmonary hypertension due to left heart 
disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3.  Pulmonary hypertension due to lung dis-
eases and/or hypoxia
3.1.  Chronic obstructive pulmonary disease 
(COPD)
3.2. Interstitial lung disease
3.3.  Other pulmonary diseases with mixed 
restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities 
4.  Chronic thromboembolic pulmonary hyper-
tension
5.  Pulmonary hypertension with unclear and/
or multifactoral mechanisms
5.1.  Haematological disorders: myeloprolifera-
tive disorders, splenectomy
5.2.  Systemic disorders: sarcoidosis, pulmo-
nary Langerhans cell histiocytosis, lym-
phangioleiomyomatosis, neurofibromatosis, 
vasculitis
5.3.  Metabolic disorders: glycogen storage dis-
ease, Gaucher disease, thyroid disorders
5.4.  Others: tumoural obstruction, fibrosing 
mediastinitis, chronic renal failure on 
dialysis
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EPIDEMIOLOGY AND SYMPTOMATOLOGY  
OF PULMONARY HYPERTENSION
The epidemiological data on the prevalence of the different PH types are not 
available. However, there are reports about PAH prevalence, revealing that 
this rare clinical condition is about 15 cases/million adult population (in-
cidence 2,4 cases/million adult population/year) [1, 6]. Several risk factors 
for PAH development have been identified, including pharmacological agents. 
They were classified as definite (usage of anorexic drugs, mainly derivatives of 
fenfluramine), likely (amphetamine, metamphetamine), possible (cocaine, some 
chemiotherapeutic agents, selective serotonin reuptake inhibitors, pergolid) 
and unlikely (oral contraceptives, estrogens), according to the strength of their 
association with PAH and their probably causal role [1]. Contrary to PAH, PH 
resulting from left heart diseases is estimated to be high; up to 60% of patients 
with severe left ventricular systolic dysfunction and up to 70% of patients with 
diastolic left ventricular failure present PH development. Moreover, all patients 
with severe mitral valve disease and up to 65% of those with symptomatic aorta 
stenosis demonstrate PH progression [1].
Similarly, PH due to lung diseases prevalence is also high; in advanced 
chronic pulmonary obstructive disease (COPD), PH is observed in about >  50% 
of patients, while in interstitial lung diseases it is in range between 32–39% [1].
The general PH symptoms, shared with all PH forms, include breathless-
ness, exertional exacerbations, fatigue, weakness, angina, syncope [1, 2]. The 
permanent consequence of an increase in pulmonary pressure, due to elevated 
pulmonary resistance and impedance of flow, is right ventricle strain resulting 
in right ventricle volume and pressure overload. It must be emphasized that 
right ventricle demonstrates a heightened sensitivity to changes in both pre- 
and afterload. Furthermore, this pathophysiological conditions lead to right 
ventricle dilation (and eventually hypertrophy), but also result in encroach-
ing on the left ventricle. That is why progressive right ventricular dysfunc-
tion contributes to low cardiac output and hypotension in patients with PH. 
Additionally, increased right ventricle wall strength predisposes to its ischae-
mia. Tricuspid regurgitation develops as a result of right ventricle dysfunction. 
There are also neurohormonal compensatory reaction observed in right-sided 
failure, involving atrial and B-type natriuretic peptides elevation in patients 
with PH and right ventricle failure. These peptides promote not only diuresis 
but also inhibit further pulmonary vasoconstriction. The final common path-
way for haemodynamic deterioration is an isolated right ventricular failure or 
because of the ventricular interdependence, both right and left ventricular in-
sufficiency leading to death [3].
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PULMONARY HYPERTENSION PATHOPHYSIOLOGY
Despite close connection and joint classification, the underlying mechanisms 
responsible for PH development in particular Dana Point classes are completely 
different. Thus, there is no common treatment option in various PH groups. 
However, whatever the predominance pathophysiological initiating event is, the 
progressive increase in pulmonary vascular resistance develops. 
In PAH, a multifactoral pathophysiology involving various biochemical path-
ways and cells is discussed. The initiative factor is still elusive, however, it 
is thought that endothelial dysfunction plays a key role in disease develop-
ment [7]. Whatever the primary event is, it leads to variable vasoconstriction, 
vascular smooth muscle and endothelial cells proliferation and in-situ throm-
bosis.  Additionally, apart from vascular medial smooth muscle, endothelial-de-
pendence proliferation, the extracellular matrix also participates in pulmonary 
vessels remodelling. Tenascin-C, elastin, fibronectin, produced in increased 
amounts together with collagen, highly expressed in medial layer, also cause 
vascular stiffness and lead to smooth muscles proliferation. These all mecha-
nisms are responsible for pulmonary vessel narrowing and vascular resistance 
increase. Pulmonary endothelium is also regarded to contribute in PH devel-
opment because it regulates resistance through a complex balance between 
vasodilatators (prostacyclins, nitric oxide) and vasoconstrictors (endothelin-1, 
thromboxane A2, serotonin), that is disturbed in PH. Moreover, pulmonary en-
dothelium also mediates growth factors inhibitors, antithrombotic mediators 
versus mitogens and prothrombic determinants, respectively [4]. As mentioned 
previously, endothelial dysfunction predisposes to an imbalance in the vasodi-
lators and vasoconstrictors production and to oversecretion of the thrombotic 
and inflammatory agents [4, 7].
The most important advancement in PAH pathophysiology in recent years 
was the revealing of mutations involving transforming growth factor beta su-
perfamily receptors. It was discovered that in familial PAH, germline muta-
tions in the bone morphogenetic protein receptor II (BMPR-II) gene occurs 
in about 70% of cases. BMPR-II mutations were also detected in 11–40% of 
spontanic, sporadic PH cases. Moreover, other mutations in the endoglin re-
ceptor and activin-like receptor 1 (ALK-1), associated with hereditary haem-
orrhagic telangiectasia, have also been thought to be characteristic for PAH 
phenotype in some families. That is why these findings seem to be one of 
the most important genetic factors predisposing to PAH, especially when re-
vealed that proteins encoded by these genes are also involved in control of 
vascular cell proliferation. It is interesting, however, that the response of vas-
cular endothelial and smooth muscle cells to bone morphogenetic protein 2 
(BMP2) depends on the anatomical localisation of the cells — those ones lo-
cated in large arteries are inhibited, while peripheral artery smooth muscle 
112
cells enhance proliferation. BMP2 proteins also regulate endothelial cells func-
tions by their protection from the apoptosis. Thus, reduced BMP2 function 
in BMPR-II receptor mutations, leads to increased endothelial apoptosis with 
subsequent damage of the endothelial barrier allowing the ingress of serum fac-
tors, promoting smooth muscle and myofibroblasts proliferation and changes 
in the matrix [7].
There are also reports that PAH is related to the auto-antibody diseases. 
About 15% of PAH patients have a connective tissue disturbances. It seems 
that an intact immune system is necessary for the protection against PAH. In 
animal models, disease progression was revealed to rely on inflammation that is 
implicated in repair and misrepair in vascular remodelling (Il-1, Il-6, RANTES, 
fractalkine were demonstrated to be upregulated). Disturbed immunity is re-
garded to be a “second hit” and cause of the worsened PAH pathophysiology [7]. 
The mechanisms of other PH types can be explained by several multiple 
mechanisms. PH due to left heart diseases develops mostly as a result of the 
passive, background transmission of the pressure elevation (post-capillary PH), 
but pathophysiology of this PH form may also include vasoconstrictive reflexes 
arising from stretch receptors located in the left atrium and pulmonary veins 
and endothelial dysfunction of pulmonary arteries leading to vessel remodel-
ling.
PH resulting from lung diseases or hypoxia is caused by hypoxic vasocon-
striction, mechanical stress of hyperinflated lungs, loss of capillares, inflamma-
tion and toxic effects of cigarette smoking. The endothelial derived imbalance 
between vasoconstrictory and vasodilatatory agents secretion is also possible. 
PH observed in pulmonary embolism depends on the mechanical obstruction 
of pulmonary arteries. The clotting formation is associated with coagulation 
process disturbances together with platelet and fibrinolysis dysfunction, that 
enable the local procoagulation environment. It is aggravated by inflamma-
tory infiltration that is found in pulmonary endarterectomy specimens. The 
pathophysiology of PH classified as group 5th, according to Dana Point grading 
(pulmonary hypertension with unclear and/or multifactoral mechanisms) is 
unclear and multifactoral [1].
CURRENT TREATMENT OF PULMONARY HYPERTENSION
Treatment of pulmonary hypertension is complex, involving both symptomatic 
and — in selected PH group — specific and causative agents. Available specific 
drugs are currently approved for the treatment of patients suffering from PAH. 
However, patients with hypoxia-induced PH or those ones with chronic throm-
boembolic PH may also benefit from these treatment. This specific PAH mana-
gement address three main aspects: 1. pulmonary vasoconstriction 2. vascular 
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obstruction by recurrent embolism or local thrombosis 3. pulmonary vascular 
remodelling, that is the most difficult to treat [8].
Basic rules should be introduced in all PH patients, regardless from the 
detailed pathomechanisms. Patients should keep their active lifestyle to main-
tain their psychological well-being and to prevent physical de-conditioning, but 
on the other hand they should avoid events leading to significant shortness of 
breath. Episodes of dizziness, near-fainting or syncopes must be considered as 
alarming signs of right ventricular insufficiency progression and require restric-
tion of physical activity to level that prevents these symptoms. Female patients 
should be advised to use contraceptives as pregnancy may induce rapid PH de-
terioration. In the case of chronic hypoxia (PaO2  <  60 mm Hg), long term oxygen 
treatment must be implemented to prevent hypoxic pulmonary vasoconstric-
tion. Moreover, patients should not exceed altitudes of 1500 m above sea level 
and supplemental oxygen is recommended for airplanes travel [8].
At present, there is neither specific therapy for PH due to the left heart 
disease nor for PH associated with COPD or interstitial lung disease. The man-
agement should be aimed at the optimal treatment of the underlying disease. 
In patients suffering from PH secondary to left heart disease, angiotensin con-
verting enzyme inhibitors or angiotensin AT1 receptor antagonists in combina-
tion with diuretics can be used to promote left ventricular re-compensation. 
Other drugs (nitrates, inotropic agents) and interventions (valvular surgery, 
resynchronisation therapy, left ventricle device implantation or heart trans-
plantation) are also to be considered. The treatment of choice for patients with 
COPD or interstitial lung disease and associated hypoxemic PH is long term 
oxygen therapy. Treatment with conventional vasodilators is not recommended 
because they may impair gas exchange due to the inhibition of hypoxic pul-
monary vasoconstriction. Patients with chronic thromboembolic pulmonary 
hypertension should receive life-long anticoagulation, usually oral vitamin K 
antagonists adjusted to a destination INR between 2 and 3 [1, 8].
The administration of — so called — specific drugs dedicated for pulmonary 
hypertension treatment is restricted to pulmonary artery hypertension — PAH. 
This specific therapy contains various agents, such as: inhalatory nitric  oxide, 
calcium channel blockers (CCB), prostacyclin and prostacyclin derivatives, 
phosphodiesterase –5 and –3 inhibitors and endothelin receptor antagonists 
(“sentans”). These pharmacological agents address the main pathophysiological 
PAH aspect — pulmonary vasoconstriction [7].
The inhalatory nitric oxide (INO) causes selective pulmonary vasodilatation, 
lowering the PAP and pulmonary vascular resistance (PVR). NO administra-
tion activates guanylate cyclase and increases guanosine 3,5-monophosphate 
(cGMP) level, resulting in pulmonary vascular smooth muscles relaxation. INO 
is a therapeutic option in short-term high pulmonary pressure restraint in 
critically ill adults, in management of acute, refractory hypoxia related to ADRS 
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and in short-term management of pulmonary hypertension in pediatric popula-
tion. INO administration is associated with some side effects, including met-
hemoglobinemia and carboxyhemoglobinemia [7, 9].
Inhibition of cGMP degradation by phosphodiesterase-5; PDE5 (and to 
a lesser extend, phosphodiesterase-3; PDE3) is an alternative pharmacological 
approach to enhance pulmonary vasodilatation. Additionally, PDE5 inhibitors 
are also suspected to exert antiproliferative effects. All PDE5 inhibitors ap-
proved for erectile dysfunction treatment cause significant pulmonary vasodila-
tation [1, 9–11]. They are mentioned in Table 2 below.
The earliest traditional vasodilators used since the 1980s were calcium 
channel blockers and nifedipine, diltiazem and amlodipine were predominantly 
used. The choice of selected CCB is based on patient’s baseline heart rate 
— a relative bradycardia favours nifedipine or amlodipine while patient with 
resting tachycardia starts with diltiazem. Limiting factors reported to be the 
most frequent adverse effects were systemic hypotension and lower limb pe-
ripheral oedema [1, 7, 10, 11]. 
The rationale for prostacyclin usage in PAH treatment is based upon the 
physiological features of this compound — it induces potent vasodilatation of 
all vascular beds and is the most potent endogenous inhibitor of platelet ag-
gregation. Moreover, it appears that prostacyclin has both cytoprotective and 
antiproliferative properties. At present, there are few prostacyclin analogues 
clinically used, that possess different pharmacokinetic profile but similar 
pharmacodynamic effects [1, 7, 9–11]. They are shortly described in Table 2 
 below. 
The endothelin-1 receptor antagonists are used in PAH treatment due to 
data supporting a prominent role of the endothelial system in PAH pathogene-
sis mentioned above. Endothelin-1 (ET1) exerts vasoconstrictor and mitogenic 
effects by binding to ETA receptors. There are also ETB ones but their activa-
tion lead to the opposite effects (vasodilatatory and antiproliferative), counter-
balancing the deleterious effects of ET1 mediated via ETA receptors. From this 
reason, there were attempts to introduce ETA receptor selective antagonists, 
since selective ETA antagonist may have advantages over non-selective inhibi-
tion. Undoubtedly, there are no premises to apply selective ETB receptor an-
tagonists [12, 13]. However, despite potential differences in receptor isoforms 
activity, the efficacy of both selective and non-selective ET1 receptor antago-
nists estimated in several studies appeared to be similar. The ETA/ETB recep-
tor antagonists (sentans) introduced to PAH therapy are given in table 2 below 
[1, 7, 9–11].
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PATHOPHYSIOLOGICAL PREMISES OF FUTURE PULMONARY  
HYPERTENSION TREATMENT
All of the current therapies that have been approved for PAH treatment, are 
focused on the vasoactive mechanisms. From the pathophysiological point of 
view, the future PAH pharmacological opportunities should be concentrated not 
only on the next generation of vasodilators but also on anti-proliferative agents 
introduction, according to the demonstrated heightened proliferation of smooth 
muscle in the small pulmonary resistance arteries. However, the advances in 
agents reversing and preventing from the vascular remodelling development are 
still insufficient, since the therapy of vascular remodelling is the most difficult 
feature to treat [1, 7].
The future antiproliferative agents include factors blocking growth factors. 
It was shown that several growth factors (platelet derived growth factor; PDGF, 
basic fibroblast growth factor; b-FGF, epithelial growth factor; EGF) are impli-
cated in the abnormal proliferation and migration of vascular smooth muscle 
cells. They also act as potent mitogen and chemoattracant for vascular smooth 
muscle cells. Growth factors activate their receptors (e.x. PDGFR) belonging 
to a family of transmembrane receptor tyrosine kinases that are autophos-
phorylated after ligand bindings. Imatinib, is a selective inhibitor of tyrosine 
kinase that was initially designed for blocking breakpoint cluster region Abel-
son (bcr-abl oncogen). Thus, this agent was approved for treatment of chronic 
myeloid leukaemia, however, it also displayed efficacy in two animal models of 
PAH, showing desired pulmonary hemodynamics and vascular remodelling im-
provement. These findings made imatinib an attractive antiproliferative agent 
in a number of settings [7, 10]. 
Recent advances have also identified GTP-ase RhoA kinase and its effector 
protein — rho kinase that play role in vascular tone and structure maintenance. 
In pulmonary vessels, rho-kinase phosphorylates and inactivates myosin light 
chain phosphatase, causing vasoconstriction. Thus, inhibition of RhoA/rho ki-
nase system promotes vasodilatation. The experimental studies demonstrated 
that treatment with fasudil — rho kinase inhibitor lead to sustained pulmonary 
vasodilatation in fetal sheep [14, 15].
The other directions focused on the next generation of vasodilatators re-
search, mostly acting via soluble guanylate cyclase (sGC). Both stimulators 
(augment the NO effects on the enzyme) and activators (mediate via NO inde-
pendent mechanisms) of sGC are studied. Riociguat (sGC stimulator) under-
went first clinical trials demonstrating significant improvement in pulmonary 
haemodynamic parameters in patients with PAH. The observed effects were 
greater than those noted by inhaled NO. Other vasodilatators such as vasoac-
tive intestinal peptide (VIP) are also particularly of interest. VIP and related 
peptides exert biological effects via specific receptors VPAC-1 and 2, with sig-
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nalling pathways involving cAMP and cGMP, both of which induce relaxation 
of vascular smooth muscle cells. Therefore VIP seems be also potential PAH 
treatment target, however, clinical data are lacking and controlled studies are 
required [7, 10]. 
On a margin it should be noticed that pulmonary hypertension develop-
ment was also observed after some anorexigenic agents (aminorex), as it was 
mentioned earlier. It became a background of serotonin PAH hypothesis, origi-
nated in the 1960s when the relationship between anorexigenic drugs and 
increased PAH risk development was revealed for the first time. In the early 
1980s the similar findings were displayed for patients receiving fenfluramine. 
These agents are serotonin transporter substrates and increase extracellular 
serotonin level — the appetite-suppressant effects of fenfluramine and its de-
rivatives is regarded to be depended on the increased serotonin release and 
augmented serotonin receptors stimulation [16]. Serotonin is thought to induce 
pulmonary hypertension by acting on specific serotonin transporters resulting 
in pulmonary arterial fibroblast and smooth muscles proliferation enhance-
ment. It leads to the thickening of the medial layer and a narrowing of the 
pulmonary arteries lumen, contributing to the vascular remodelling and in 
consequence resulting in vasoconstriction and pulmonary resistance increase. 
The experimental data confirm serotonin role in PAH development — this com-
pound can potentiate the development of hypoxia-induced PAH in rats. The ex-
act mechanism by which serotonin induces PAH has not been clearly described 
so far, however the interactions between serotonin and BMP system have been 
reported — increased serotonin signalling may provide a second risk factor 
which can mediate PAH in patients with a mutation in BMPR-II gene [16]. It is 
unknown, if agents changing serotonin transporters functioning (selective sero-
tonin reuptake inhibitors?), may be valuable in PAH — therapeutic approaches 
that challenge the function of the serotonin transporters and receptors in PAH 
patients have not been tested [16–19].
There are also interesting reports suggesting the potential benefit role of de-
hydroepiandrosterone (DHEA) in PAH. DHEA is a steroid hormone derived from 
cholesterol in adrenal glands. In contrast to other steroid hormones, no selective 
receptor for DHEA has been found. DHEA is converted into androgens/estro-
gens, thus it is unknown if DHEA can exert its effects through these receptors 
directly or by its metabolites, however, the common belief exists that DHEA is 
a poor agonist of estrogen receptors. Pharmacodynamic studies revealed that 
this hormone hyperpolarizes the membrane affecting K Ca channel and acts as 
a BK Ca opener. Moreover, in experimental studies it was shown that DHEA 
 induces the up-regulation of pulmonary artery soluble guanylate cyclase pro-
tein expression and increases pulmonary artery vasodilator responsiveness to 
nitric oxide. DHEA also decreases the hypoxia-induced factor 1 (HIF-1α) in pul-
monary vascular smooth muscle cells. There are also experimental preliminary 
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results demonstrating that chronic (three weeks and more) DHEA administra-
tion in rats prevented RhoA kinase overactivity. Thus, it seems be possible that 
DHEA may be included into new class of pharmacological agents applying in 
PAH treatment — inhibitors of RhoA kinase system [20].
In summary, current pharmacological directions in searching of new agents 
in PAH treatment are listed in table 3 below. 
T a b l e  3  —  T a b e l a  3
Future possible pharmacological options in PAH treatment
Przyszłe możliwe opcje farmakoterapii nadciśnienia płucnego
Group Pharmacological agents under invastigations
Phosphodiesterase-3 inhibitors
(PDE3-Inhibitors)
minrinon 
Soluble guanylate cyclase (sGC) activators riociguat
Inhaled vasoactive intestinal peptide in experimental studies at present
tyrosine kinase inhibitors 
(platelet-derived growth factor inhibitors) 
imatinib
vascular endothelial growth factor receptor 
inhibitors
in experimental studies at present
Rho-kinase inhibitors fasudil
selective serotonin reuptake inhibitors (SSRI) in experimental studies at present
Łukasz Dobrek, Piotr thor 
PATOFIZJOLOGICZNE POSTĘPY W LECZENIU NADCIŚNIENIA PŁUCNEGO
Streszczenie
Nadciśnienie płucne jest chorobą o wciąż nie w pełni poznanej patofizjologii. Możliwości aktu-
alnego leczenia farmakologicznego w tym zaburzeniu są, niestety, relatywnie niewielkie, dlatego 
trwają poszukiwania nowych związków skutecznych w leczeniu tego schorzenia. Artykuł krótko 
przedstawia obecną klasyfikację nadciśnienia płucnego, główne elementy jego etiopatogenezy oraz 
aktualne i potencjalne możliwości interwencji farmakologicznej.
REFERENCES
1. Galie N. (ed.): Guidelines for the diagnosis and treatment of pulmonary hypertension. The 
task force for the diagnosis and treatment of pulmonary hypertension of the European Society 
of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International 
Society of Heart and Lung Transplantation (ISHLT). European Heart Jounal 2009, 30: 2493–2537. 
120
— 2. Liu C., Liu K., Ji Z., Liu G.: Treatments for pulmonary arterial hypertension. Respiratory 
Medicine 2006, 100: 765–774. — 3. Zamanian R.T., Haddad F., Doyle R.L., Weinacker A.B.: Man-
agement strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care 
Med 2007, 35: 2037–2050. — 4. Yildiz P.: Molecular mechanisms of pulmonary hypertension. 
Clinica Chimica Acta 2009, 403: 9–16. — 5. Wolfren S.A., Grunberg K., Vonk Noordeegraaf A.: Diag-
nosis and management of pulmonary hypertension over the past 100 years. Respiratory Medicine 
2007, 101: 389–398. — 6. Peacock A.J., Murphy N.F., McMurray J.J.V., Caballero L., Steward S.: 
An epidemiological study of pulmonary arterial hypertension. Eur Res J 2007, 30: 104–109. 
— 7. Toshner M., Tajsic T., Morrell N.W.: Pulmonary hypertension: advances in pathogenesis and 
treatment. British Medical Bulletin 2010, 94: 21–32. — 8. Ghofrani H.A., Voswinckel R., Reichen-
berger F., Weissmann N., Schermuly R.T., Seeger W., Grimminger F.: Hypoxia- and non-hypoxia 
related pulmonary hypertension — established and new therapies. Cardiovascular Research 2006, 
72: 30–40. — 9. Haj R.M., Cinco J.E., Mazer C.D.: Treatment of pulmonary hypertension with 
selective pulmonary vasodilators. Curr Opin Anaesthesiol 2006, 19: 88–95. — 10. Ghofrani H.A., 
Voswinckel R., Reichenberger F., Weissmann N., Schermuly R.T., Seeger W., Grimminger F.: Hypoxia 
and non-hypoxia related pulmonary hypertension — established and new therapies. Cardiovas-
cular Research 2006, 72: 30–40. 
11. Liu C., Liu K., Ji Z., Liu G.: Treatments for pulmonary arterial hypertension. Respiratory 
Medicine 2006, 100: 765–774. — 12. Dobrek Ł., Thor P.: Endotelina w patofizjologii chorób sercowo- 
-naczyniowych. Polski Merkuriusz Lekarski 2010, XXVIII (166): 289–292. — 13. Dobrek Ł., Thor P.: 
Antagoniści endoteliny i ich znaczenie w farmakoterapii. Polski Merkuriusz Lekarski 2010, XXVIII 
(167): 404–406. — 14. Abman S.H.: Recent advances in the pathogenesis and treatment of per-
sistent pulmonary hypertension of the newborn. Neonatology 2007, 91: 283–290. — 15. Oka M., 
Fagan K.A., Jones P.L., McMurtry I.F.: Therapeutic potential of RhoA/Rho kinase inhibitors in 
pulmonary hypertension. British Journal of Pharmacology 2008, 155: 444–454. — 16. Demp-
sie Y., MacLean M.R.: Pulmonary hypertension: therapeutic targets within the serotonin system. 
British Journal of Pharmacology 2008, 155: 455–462. — 17. Eddahibi S., Humbert M., Fadel E., 
Raffestin B., Darmon M., Capron F.: Serotonin transporter overexpression is responsible for pul-
monary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical 
Investigation 2001, 108: 1141–1150. — 18. Guignabert C., Raffestin B., Benferhat R., Raoul W., 
Zadigue P., Rideau D.: Serotonin transporter inhibition prevents and reverses monocrotaline-
induced pulmonary hypertension in rats. Circulation 2005, 111: 2812–2819. — 19. Long L., 
MacLean M.R., Jeffery T.K., Morecroft I., Yang X.D., Rudarakanchana N.: Serotonin increases sus-
ceptibility to pulmonary hypertension in BMPR2-deficent mice. Circulatory Research 2006, 98: 
818–827. — 20. de la Roque E.D., Savineau J.P., Bonnet S.: Dehydroepiandrosterone: a new treat-
ment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacology 
and Therapeutics 2010, 126: 186–199.
Pathophysiology Department 
Jagiellonian University Medical College 
ul. Czysta 18, 31-121 Kraków
Corresponding author:
Łukasz Dobrek MD, Ph.D. 
Department of Pathophysiology 
Jagiellonian University Medical College 
ul. Czysta 18, 31-121 Kraków 
lukaszd@mp.pl
